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Multistage Carcinogenesis in the
Urinary Bladder
By Samuel M. Cohen,* Robert E. Greenfieldt
and Leon B. Ellweint
The induction of cancer of the urinary bladder is a multi-stage process involving multiple exoge-
nous and endogenous factors. Based on the classical initiation-promotion model, we have used N-[4-
(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) as initiator and sodium saccharin (SAC) or trypto-
phan as promoters. These latter chemicals have the properties expected of promoters: induction of
hyperplasia, reversibility and nonmutagenicity. Also, tumors were induced whether the promoter
was administered immediately after FANFT or beginning 6 weeks after FANFT was discontinued,
but no tumors resulted if either promoter was given without initiation with FANFT. Factor(s) pres-
ent in normal urine also are involved in the promotion process, in addition to the role of urine as a
carrier of carcinogens. However, administration of SAC to animals with a rapidly proliferating
bladder mucosa, induced by ulceration, pellet insertion, or in utero, resulted in bladder tumor induc-
tion, even without prior initiation with FANFT. To better understand the complex interaction of the
multiple variables in bladder carcinogenesis, a stochastic computer model has been formulated
based on long-term carcinogenicity and tissue kinetic studies in vivo. This model indicates the im-
portance of cell proliferation and the development of hyperplasia in carcinogenesis.
Urinary Bladder Cancer Induced
by FANFT
Several chemicals have been identified which in-
duce bladder cancer in humans and in experimental
animals (1,2). Several of these, such as 2-acetylami-
nofluorene (AAF), induce tumors of other tissues in
experimental animals, particularly the liver and
breast. In the 1960's chemicals were identified
which were bladder specific carcinogens, including
N-butyl-N(4-hydroxybutyl)nitrosamine (BBN) admin-
istered in the drinking water (3), N-[445-nitro-2-
furyl)2-thiazolyl]formamide (FANFT) administered
in the diet (4) or N-methyl-N-nitrosourea (MNU)
administered by intravesical instillation (5). We
have utilized the FANFT bladder cancer model. It
was originally described in female Sprague-Dawley
rats (6), but our experiments have been performed
in the model developed in inbred male Fischer rats
by Tiltman and Friedell (7).
Tiltman and Friedell (7).
The details of this model and its pathogenesis
have been described (7-10). Briefly, the bladder epi-
thelium progresses from the normal three cell layer
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urothelium to a simple hyperplasia, followed by fo-
cal nodular and papillary hyperplasia, papillomas
and finally carcinomas. These carcinomas produce
marked hematuria and frequently become invasive.
Distant metastases occur but are relatively rare in
this model, and hydronephrosis is also uncommon.
A dose response is observed, and a 100% incidence
of bladder tumors is induced if the FANFT is ad-
ministered at a dose of 0.05% of the diet or higher
(11).
For the remainder of the experiments to be de-
scribed, FANFT was administered in the diet at a
dose of 0.2%. To determine the reversibility or irre-
versibility of the early hyperplastic changes in blad-
der carcinogenesis, FANFT was fed in the diet for
different periods of time followed by control diet un-
til 1 (8), 11/2 (10), or 2 years (12-14). It was shown that
FANFT administered in the diet for 6 weeks or less
induced a simple hyperplasia which regressed with-
in 2 weeks after discontinuing the diet. The blad-
ders remained normal through 11/2 years, but a few
animals fed FANFT for 6 weeks developed bladder
tumors by the end of 2 years. Rats fed FANFT for
8 or 10 weeks showed partial regression of the nod-
ular and papillary hyperplasia when FANFT was
discontinued in the diet, but the bladders never re-
turned to normal. By 1 year many of these animals
had developed tumors, and by 2 years most of them
had developed bladder cancer. Animals fed FANFTCOHEN, GREENFIELD AND ELL WEIN
for 12 weeks or more at a level of 0.2% of the diet
had lesions which continued to progress even after
FANFT was discontinued in the diet, and all of
these animals eventually developed bladder cancer.
Initiation and Promotion in Urinary
Bladder Carcinogenesis
The above studies involved the administration of
a single carcinogen resulting in the induction of uri-
nary bladder cancer. In contrast, humans are ex-
posed to a multitude of chemicals, some of which
may be bladder carcinogens. Ito and his colleagues
in 1976 reported that the simultaneous adminis-
tration to rats of subcarcinogenic doses of four
known bladder carcinogens, BBN, AAF, FANFT,
and 3, 3'-dichlorobenzidine, resulted in the induction
of bladder cancer, whereas administration of any
one of the chemicals at the doses used did not (15).
In addition, they demonstrated that if the chemicals
were administered sequentially rather than simulta-
neously bladder cancer also was induced (16). These
studies involved the use of"complete" carcinogens.
Studies involving the use of the pellet implanta-
tion technique in mice suggested that a process
similar to initiation and promotion as originally de-
scribed in the mouse skin model was applicable to
the urinary bladder. If a cholesterol pellet contained
the 8-methyl ether of xanthurenic acid (XAE), a
tryptophan metabolite, an increased incidence of
bladder tumors was induced compared to the cho-
lesterol pellet alone. However, a similar incidence of
tumors was induced if the XAE was administered
by subcutaneous injection rather than in the pellet,
and the cholesterol pellet without XAE was subse-
quently implanted into the bladder (17).
Similar results were demonstrated using 2-amino-
diphenylene oxide administered orally with a paraf-
fin pellet in the bladder (18). However, the role of
the pellet in these experiments is unclear (19).
More typical models of initiation and promotion
were subsequently demonstrated for the urinary
bladder by using MNU (20), FANFT (12-14), or BBN
(21, 22) as the initiator, and sodium saccharin, sodi-
um cyclamate, tryptophan, or phenacetin as the pro-
moter. Described below are the studies performed
in our laboratory using FANFT as the initiator and
either sodium saccharin or tryptophan as the pro-
moter.
We initially demonstrated that if FANFT was ad-
ministered in the diet at 0.2% for 6 weeks, the inci-
dence of bladder tumors was significantly increased
if either sodium saccharin or D,L-tryptophan was ad-
ministered, either immediately after the FANFT or
after a 6-week delay period, during which time the
animals were fed control diet. This 6-week delay
was chosen to allow for complete evacuation of
FANFT from the animal (23), for the simple hyper-
plasia present at the end of 6 weeks to regress so
the bladder had returned to normal morphologically
(8) and also to provide some evidence that the pro-
cess of initiation in the urinary bladder was irrever-
sible similar to that described in other tissues (24,
25). However, this dose of FANFT was not subear-
cinogenic when the animals were allowed to live for
2 years. Rather, a small incidence of tumors was in-
duced. We repeated this experiment using four
weeks of FANFT as the initiator followed immedi-
ately by either sodium saccharin or L-tryptophan
(13). Again a significant, although considerably
lower incidence of tumors was induced compared to
using six weeks of FANFT as the initiating dose. v-
Tryptophan was used in this experiment rather
than the D,L-racemic mixture since the I-form
became economically available commercially.
Sodium saccharin and L-tryptophan (or its metab-
olites) have many of the properties known for pro-
moters in other tissue systems. Neither compound
or the metabolites or tryptophan is mutagenic in
the usual in vitro assays (26), although some do
cause genetic alterations such as increased recombi-
nation (27). These latter genetic alterations have
also been found with promoting agents for other tis-
sues (28). Also, both agents induce increased cell
proliferation (hyperplasia) in the target organ even
without prior initiation (29, 30). If either compound
is administered alone, bladder tumors are either not
induced or induced at low incidence (1, 26).
Effect of Regenerative Hyperplasia
in Urinary Bladder Carcinogenesis
The urinary bladder epithelium is normally mito-
tically quiescent; the labelling index is approxi-
mately 4 per 10,000 cells (29, 31). Considerable evi-
dence has accumulated suggesting that initiation oc-
curs only during the cell cycle, not when the cell is
at rest (25). We postulated that if the proliferation
rate of the urinary bladder epithelium were in-
creased, it may be more susceptible to the adminis-
tration of an initiator such as FANFT, which under
usual circumstances requires a relatively long
period of administration for initiation to occur. We
therefore performed the experiment shown in Table
1 (14). Regenerative hyperplasia was induced either
by the freeze ulceration technique of Shirai et al.
(14, 32) or by intraperitoneal injection of cyclophos-
phamide (33). With either of these techniques ulcer-
ation of the bladder epithelium occurs with con-
sequent regenerative hyperplasia and eventual re-
pair. The peak hyperplastic response occurs be-
tween 3 and 7 days, but remains present for approx-
imately 3 to 4 weeks. The mitotic rate of the uri-
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Table 1. Effect of regenerative hyperplasia on bladder carcinogenesis.a
Effective Bladder tumorsc
No. Groupb no. of rats Papilloma Carcinoma Total
1. Ul-FANFT- Sc 23 0 4(17) 4(17)
2. Ul-FANFT 22 0 0 0
3. Ul-Cont-S 20 1(5) 5(25) 6(30)
4. Ul 23 0 0 0
5. FANFT-'bS 21 0 1(5) 1(5)
6. FANFT 19 0 0 0
7. S 17 0 0 0
8. FANFT-uUl-*S 22 1(5) 8(36) 9(41)
9. FANFT-Ul 21 0 2(10) 2(10)
10. Ul- S 21 2(10) 2(10) 4(20)
11. CP-FANFT--S 22 3(14) 4(18) 7(32)
12. CP-FANFT 9 0 0 0
13. CP-Cont-S 17 2(12) 3(18) 5(30)
14. CP 7 1(14) 0 1(14)
15. CP-S 17 3(18) 3(18) 6(36)
16. Cont 32 0 0 0
17. S 20 0 0 0
aData from Cohen et al. (14).
bUl, ulcer by freezing; S, sodium saccharin as 5% of diet; FANFT, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide as 0.2% of diet for
2 weeks; CP, single IP injection of cyclophosphamide, 100 mg/kg.
eNumbers in parentheses represent the percentage of the rats in a group with the given lesion.
nary bladder is markedly increased during this
period and nodular and papillary formation occurs.
However, in both instances, the hyperplasia is com-
pletely reversible if the animals are maintained up
to two years after the ulceration event; there is no
formation of tumors (14, 33, 34). FANFT was admin-
istered for 2 weeks immediately after the ulceration
event and then promoted with sodium saccharin for
the remaining 102 weeks of the experiment. After
either method of ulceration, bladder tumors were
induced if the rats also were fed FANFT and sodi-
um saccharin. However, bladder tumors also oc-
curred if ulceration by either method was followed
by sodium saccharin without FANFT. The results
were similar whether sodium saccharin was fed im-
mediately or after a two week delay during which
time the control diet was administered. Incidences
were similar to those in which FANFT was adminis-
tered. Two weeks of FANFT, sodium saccharin, or
the ulceration alone did not induce tumors.
These data suggest that sodium saccharin admin-
istered to an animal with a rapidly proliferating uri-
nary bladder epithelium is carcinogenic. This is a
similar situation to the previous two-generation
studies with sodium saccharin in rats (35) and the
pellet implantation experiment in mice (36). In both
of these instances, sodium saccharin is administered
to an animal with a rapidly proliferating bladder ep-
ithelium: the fetal bladder in utero in the two-gener-
ation study and the surgically incised and sutured
bladder in the pellet implantation experiment. In
the latter experiment the process of implanting a
pellet into the bladder results in a regenerative hy-
perplasia and repair of the incision with similar tis-
sue kinetics as those following freeze ulceration or
cyclophosphamide. In the pellet implantation experi-
ments, the pellet may be acting as a continuous
stimulus for epithelial proliferation.
This experiment would also suggest that urinary
bladder carcinogenesis can occur without mutation
occurring. In this situation, mutation is strictly de-
fined as a change in nucleotide content as would be
detected in in vitro assays such as the Ames assay.
However, other types of genetic alteration, such as
recombination, translocation, or increased ploi-
dyism, might be involved. Lack of mutation is sup-
ported by the findings that the incidence of tumors
with ulceration followed by sodium saccharin was
not increased if FANFT was administered for a
period of 2 weeks immediately after the ulceration,
and there was no increased incidence if ulceration
was induced by cyclophosphamide versus freezing.
FANFT (37) and cyclophosphamide (38) adminis-
tration each result in urine with marked mutagenic
activity.
The Role of Urine in Bladder
Carcinogenesis
Experiments in dogs using aromatic amines as
the carcinogens demonstrated the role of urine as a
carrier of carcinogens (1, 2). This theory has been
based on the ability of the kidney to concentrate
various substances to higher levels in the urine
than in the serum. Such concentration would result
in a greater exposure to the bladder epithelial cells
to the carcinogen by way of the urine than would be
211COHEN, GREENFIELD AND ELLWEIN
possible by diffusion from the serum, through the
subepithelial capillaries, across the basement mem
brane into the epithelium. The pharmacodynamics
of urinary bladder carcinogenesis must be borne in
mind when attempting to affect the process, as de-
scribed elsewhere in this symposium (39).
However, beginning with experiments reported
by Chapman et al. (40), evidence has accumulated
suggesting that urine or substances in urine play a
more direct role in bladder carcinogenesis than
merely transporting carcinogens. In the experi-
ments by Chapman et al. (40), the urinary bladder
was divided in half and a pellet was inserted into
each half. The dome half of the bladder did not have
exposure to urine flow, whereas the lower half-the
trigone portion-of the urinary bladder was ex-
posed to urine by the usual flow from the ureters.
The portion of the bladder exposed to urine and
containing a pellet developed tumors, but the
portion containing the pellet without exposure to
urine did not develop tumors. As mentioned above,
the role of the pellet in these experiments com-
plicates the interpretation.
More direct evidence for a role of urine in blad-
der carcinogenesis was provided by a series of ex-
periments by Oyasu and Rowland and their col-
leagues (41-44). If FANFT was administered to male
Fischer rats for 14 weeks followed by control diet,
the rats developed bladder tumors by 30 weeks of
the experiment, as had been shown in several previ-
ous experiments by others (8). However, if the rats
underwent bilateral ureterosigmoidostomies at the
time FANFT was discontinued at the end of 14
weeks of administration, effectively diverting the
flow of urine away from the bladder to the colon, a
markedlydecreased incidence of bladder tumors was
induced (41). Thus, even though a supposedly carcin-
ogenic dose of FANFT had been administered, it
was necessary for urine to be present for expres-
sion of these tumors. Similarly, by using the hetero-
topic bladder model, a direct action for urine was
again demonstrated (42). The bladder was exposed
to 4 weeks of BBN administration and then trans-
planted to the back of another rat and attached to a
reservoir through which various substances could
be injected. These bladders developed tumors if
urine was injected into them. However, if saline was
injected instead of urine, a markedly decreased inci-
dence of tumors resulted. The saline and urine were
adjusted to be of equal pH and osmolality. Using an
in vitro assay for ornithine decarboxylase activity
and cell proliferation, Oyasu and his colleagues were
able to demonstrate that most of the activity in
urine was present in the molecular weight fraction
greater than 10,000 daltons (43) and confirmed this
finding in the heterotopic bladder model (44).
These experiments suggest that the early events
in carcinogenesis of the urinary bladder can be in-
duced by a variety of substances such as FANFT
and that if they progress far enough, the urine will
act as an enhancing substance, possibly by simply
maintaining an increased proliferative rate of the
bladder epithelium.
A Probabilistic Model of Urinary
Bladder Carcinogenesis
The above experiments and others provide sup-
port for the hypothesis that carcinogenesis occurs in
two steps. Because of the complexity, the interrela-
tionships of the biological events are difficult to
evaluate by use of in vivo models. Another ap-
proach is to examine specific questions in tissue cul-
ture systems. However, there are certain limita-
tions within these systems also, which have been
well documented in the literature. Another ap-
proach is to utilize a computer-based model which
can analyze the interrelationships in mathematical
terms and thus provide an aid in identifying critical
experiments necessary for furthering our under-
standing of carcinogenesis.
We have devised a computer-based, probabilistic
model of two-stage carcinogenesis (45) using data
from the urinary bladder carcinogenesis experi-
ments described above. However, the concepts and
the basic model are applicable to other tumor sys-
tems as well. For this model, several assumptions
had to be made concerning the carcinogenic process.
The first is that the process requires at least two
specific events which are irreversible. Secondly,
these critical events can occur only during cell repli-
cation; they cannot occur when the cell is at rest (25,
46). Thirdly, the critical events occur only in stem
cells in the urinary bladder. This could be a stem
cell equivalent in other tissues. Our model is proba-
bilistic. In the normal situation, each event is obvi-
ously rare.
The various possible cellular transitions are
depicted in Figure 1. The critical transitions for car-
cinogenesis are from normal stem cell to initiated
stem cell to transformed stem cell. The probability
of a single normal cell becoming initiated during cell
replication is given as p12, and the probability of an
individual initiated stem cell becoming a trans-
formed stem cell is given as p2. In the urinary blad-
der of the rat there are approximately 10 cells, and
we estimate that approximately 105 are stem cells.
The likelihood of developing a tumor within a speci-
fic period of time is thus a function of: the number
of cells in each of the stem cell populations, the
number of mitotic events in each stem cell popula-
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FIGURE 1. Possible cellular transitions.
tion during this time period and the probabilities P12
and p2. The number of cells can be estimated by the
histopathologic examination of the bladder at dif-
ferent time periods following various stimuli, such
as FANFT or sodium saccharin, and the mitotic
rate can be determined experimentally by autoradi-
ography. Obviously, estimates need to be made of
the transition probabilities, p12 and p,. It should be
recognized that the stimulus can cause any of the
above parameters to change in value as a function
of time.
In the FANFT Fischer rat model, it has been
shown that hyperplasia (an increase in the number
of cells) appears rapidly and gradually increases
with time of administration of the chemical (7, 8). In
addition, the mitotic rate increases. In the revers-
ibility-irreversibility study of the various early
lesions described above (8-10), it was also shown
that the cell population sizes decrease if FANFT is
withdrawn from the diet. The computer-based
model reflects these changes over time for 1-day in-
crements. By using the data from the above experi-
ments as model input, predictions can be made of
the rate of tumor formation and growth. Based on
this model, we are able to show that pl2 must in-
crease dramatically above background levels during
FANFT administration, but the transition probabil-
ity p,, does not change from background. In fact, p23
must remain at background levels for the model to
replicate empirically observed tumor incidences. So-
dium saccharin was shown by the computer model
not to alter eitherp12 orp2, The entire effect of sodi-
um saccharin can be explained on the basis of in-
creased cell numbers (hyperplasia) and increased mi-
totic rate, which have been demonstrated experi-
mentally (29).
Although this model involves two events in car-
cinogenesis, it is a more general formulation than
the classical initiation and promotion concept de-
scribed originally in mouse skin (24, 25). Thus, an in-
crease in tumor incidence will occur by application
of any agent which increases any of the critical vari-
ables: The number of normal stem cells, the mitotic
rate of normal stem cells, the probability of the
transition from normal to initiated stem cell (p2), the
number of initiated stem cells, the mitotic rate of
initiated stem cells and the probability of the transi-
tion from initiated stem cell to transformed stem
cell (p.). Also, using such a model, one can demon-
strate that the critical factors in most promotion ex-
periments, including those in mouse skin with phor-
bol esters, involve an increase in the stem cell popu-
lation and an increased mitotic rate rather than an
actual change in p2,. The various properties of the
classical initiation and promotion experiments, such
as irreversibility of initiation, importance of se-
quence of administration and even the subdivision
of promotion into various stages, can be readily ex-
plained with such a model. The importance of
changes in stem cell population size and mitotic
rates appears to have been underestimated.
We believe that synthesis of data from various
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animal studies through computer-based modeling is
a valuable, relatively low cost and rapid approach
toward furthering the understanding of the com-
plex interrelationship between multiple exposures
to exogenous or endogenous agents and the devel-
opment of tumors. Also, the availability of a model
applicable to animals and man will assist in the ex-
trapolation of animal data to human problems.
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